TOURMALINE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.45 USD | -1.54% |
|
-7.62% | -48.62% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 532.4 | 344.9 | - | - |
| Enterprise Value (EV) 1 | 532.4 | 34.25 | -84.75 | 27.45 |
| P/E ratio | -2.95 x | -4.57 x | -4.43 x | -3.81 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 34.5 x | 34.5 x |
| EV / Revenue | - | - | -8.48 x | 2.74 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -0.51 x | 1.25 x | -0.4 x |
| FCF Yield | - | -195% | 80.2% | -253% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 20,337 | 25,647 | - | - |
| Reference price 2 | 26.18 | 13.45 | 13.45 | 13.45 |
| Announcement Date | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 10 | 10 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -45.41 | -84.41 | -87.67 | -104.5 |
| Operating Margin | - | - | - | -876.68% | -1,044.81% |
| Earnings before Tax (EBT) 1 | - | -42.12 | -68.51 | -97.22 | -121.5 |
| Net income 1 | -19.7 | -42.12 | -71.85 | -86.91 | -106.8 |
| Net margin | - | - | - | -869.08% | -1,068.25% |
| EPS 2 | -1.790 | -8.870 | -2.940 | -3.036 | -3.532 |
| Free Cash Flow 1 | - | - | -66.67 | -68 | -69.33 |
| FCF margin | - | - | - | -680% | -693.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -8.932 | -14.89 | -17.52 | -20.42 | -22.06 | -24.58 | -20.3 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.015 | -12.9 | -13.31 | -18.27 | -18.19 | -18.74 | -20.3 |
| Net income 1 | -7.015 | -12.9 | -13.31 | -17.21 | -18.4 | -20.59 | -20.3 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -1.640 | -0.8100 | -0.5500 | -0.6780 | -0.7240 | -0.8020 | -0.8300 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/14/23 | 3/19/24 | 5/13/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 311 | 430 | 318 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -66.7 | -68 | -69.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | -5.920 | - | - | - |
| Capex 1 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.45
USD
Average target price
58.33
USD
Spread / Average Target
+333.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.62% | 345M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.37% | 22.1B | |
| -8.14% | 18.34B | |
| -41.70% | 16.59B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- TRML Stock
- Financials Tourmaline Bio, Inc.
